On multiple occasions, this low float profile has demonstrated the ability to break out in epic fashion.
Here's a handful of times over the past year to take note of:
- On 12/16/20, JUPW hit a low of $4.47 before surging to a high of $8.35 one day later. That $3.00+ move resulted in JUPW rocketing 86%.
- On 1/11/21, JUPW blazed $2.00+ from an open of $5.02 to a high of $7.63. That move resulted in a 51% run intraday.
- On 2/23/21, JUPW moved a $1.00+ from an open of $6.15 to a high of $7.70 for an overall intraday breakout of 25%.
- On 3/5/21, JUPW dropped to a low of $4.30 before shooting $2.00+ to a high of $6.66 on 3/11/21. That short term breakout resulted in a move of 54%.
Now, this is only a handful of instances. Just take a look at the chart above and you can see all the times this profile moved quickly in the short term.
No. 3 Potential JUPW Catalyst - Big Licensing News Friday
Jupiter Wellness Licenses Photocil(TM), a Novel Topical Treatment of Psoriasis, Vitiligo, Pruritis and Atopic Dermatitis
JUPITER, FL / ACCESSWIRE / July 9, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced they have entered into an exclusive agreement to license Photocil™, a novel patented topical cream that provides clinically-proven relief for Psoriasis, Vitiligo and Atopic Dermatitis.
The Agreement signed with the Applied Biology ("AB") whereby Jupiter Wellness is the exclusive licensee for Photocil in the United States. Under the terms of the Agreement, Jupiter Wellness has use of the copyrights, patents, technology, know-how, trademarks and trade-secrets of AB related to the use of Photocil. Jupiter Wellness has the exclusive right to use the IP (including US Patent number 10,111,821) solely in connection with the manufacture, marketing, advertising, promotion and distribution of Photocil™ for the treatment of skin conditions including Psoriasis and Vitiligo.
Photocil™ is already sold in Europe, Asia and the Middle East as Presilux™ and MediSun. The licensing of Photocil™ extends and complements the Jupiter Wellness strategy for the treatment of skin diseases such as Eczema, Psoriasis and Vitiligo. Jupiter Wellness previously reported that in a double-blinded, placebo controlled clinical trial, JW-100, its novel topical formulation containing CB and Aspartame, was shown to significantly reduce the ISGA score in 50% of atopic dermatitis patients after two weeks of use.
"Licensing of Photocil™ allows Jupiter Wellness to offer additional treatments to patients suffering from skin ailments and AM/PM or combination therapy. We plan to register Photocil with the FDA and begin marketing the product immediately," stated Dr Glynn Wilson, Chief Scientific Officer of Jupiter Wellness.
Read the full article here.
No. 4 Potential JUPW Catalyst - Publishing Of Clinical Study Results
Results of Clinical Study Showing That JW 100 Significantly Reduces ISGA Score in Atopic Dermatitis (AD) Published
JUPITER, FL / ACCESSWIRE / June 22, 2021/Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced the publication of clinical study results to investigate the safety and efficacy of JW-100 its proprietary lotion formulation for the treatment of atopic dermatitis (eczema).
J Cosmet Dermatol 2021 May 31: Online ahead of print. The peer-reviewed publication reports on a double-blinded placebo-controlled study randomizing patients to one of three treatment groups: JW-100 (CB plus Aspartame), CB only, or placebo topical formulations. The Investigator's Static Global Assessment (ISGA) score was used to document any changes in AD resulting from the applied interventions at 14 days.
Dr Glynn Wilson, Chief Scientific Officer of Jupiter Wellness commented, "Peer-reviewed publication of data from controlled clinical trials conducted by leading clinicians is central to our overall strategy of developing novel medicinal products that have demonstrated safety and efficacy and ultimately receive regulatory approval."
Brian John, CEO of Jupiter Wellness added "We are excited by these initial results and the potential for JW-100 to provide a solution superior to existing prescription dr-ugs. The early clinical data shows JW-100's potential to disrupt the Bn-dollar market for the treatment of eczema."
Read the full article here.
No. 5 Potential JUPW Catalyst - Signing Of Potential Game-Changing LOI
Jupiter Wellness Enters into LOI to Acquire JustCB and its Affiliates
Brian John, CEO of Jupiter Wellness commented, "... We believe this acquisition will be highly accretive to Jupiter and its shareholders and puts us at the forefront of CB consumer related products on the market."
Nasdaq Profile (JUPW) Recap: Top Potential Catalysts
#1. Low Float
#2. History Of Short Term Breakout
#3. Big Licensing News Friday
#4. Publishing Of Clinical Study Results
#5. Signing Of Potential Game-Changing LOI
Coverage is officially initiated on JUPW. When you have time later, do this: